Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

helpline

- PMLiVE

UCB releases new data on Bimzelx for hidradenitis suppurativa

The disease affects around 1% of the population in most studied countries

- PMLiVE

UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

The study demonstrated a sustained reduction in seizures for patients

- PMLiVE

Medical Misinformation and Sensationalism in the Age of Social Media

In today’s digital age, misinformation spreads faster than ever, often driven by sensational headlines and influencer content. These sources of misinformation often overshadow evidence-based content, creating confusion for both healthcare...

Medscape Education

- PMLiVE

UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

- PMLiVE

UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

QR codes for prescribing info

Leveraging the ABPI QR Code Update: Enhancing Prescribing Information Through Best Practices

ABPI's recent update permits QR codes in printed pharmaceutical materials for prescribing information. By ensuring visibility, providing clear instructions, linking directly, and keeping content current, companies can enhance accessibility, ensure...

Genetic Digital

Accession Logo

Accession announces major UK market access consulting milestone

February 5th 2025: Today Accession Healthcare Consulting Ltd (Accession) has announced the achievement of a major consulting milestone as it enters its 15th year as a specialist provider of UK...

Accession

- PMLiVE

Stacking the odds in your favour with landscape analysis

By James Aird and Jess Choi

Amiculum

- PMLiVE

UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects approximately one in every 100 people in the US

- PMLiVE

UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab

The drug showed benefits across key secondary endpoints, including tau accumulation

- PMLiVE

UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa

The inflammatory skin disease affects about 1% of the population in most studied countries

- PMLiVE

Championing people-powered communications in rare diseases: AMICULUM’s feature in The Guardian Rare Diseases Campaign 2024

By Ellie Thomas

Amiculum

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links